KCQs
Cochlear are leaders in hearing
technology, this is through their extensive research into the different ways of
solving the hearing loss problems. They rely heavily on government funding to keep moving forward in their research and development. But
what would happen if the government took back it’s funding? Could the company
somehow still support its research and production of hearing technology?
This company has got a new device
that is called the ‘Nucleus 6’, it is the most advanced model to date. What
happens to the company if, in hypothetical terms, this product was found to
have faults after they have released it. Could the company survive and move
forward after the recall of all the products and reimbursements?
As stated earlier, Cochlear relies heavily on government funding. So what would happen if the products where
faulty or the research into new technology was a stand still, would the
government still give this company the grant money?
With this company having a huge
share base, how much would the shares be worth to the shareholders if this
company had a problem in their business (recall of products, Law suits, ect)?
Net debt is up (they have more debt this year compared to assets) - they say this is due to the purchase of another company, was this a good purchase? What does this company do?
Trade receivables were up (more customers owe them more money) - what kind of risk does this present? Can they still pay their day-to-day running costs?
They also say that their sales were not as high as expect as some customers hold of updates until newer software is available. Are these updates bringing real benefits or just marginal improvements?
Nucleus 6 approved in Europe, but only limited is USA – when is full approval expected in USA and other markets?
Have Cochlear got any emerging competition that may take over or have a big impact on the future of Cochlear? If they do what stage are they at? Have they got any working prototypes, are they ready to release a new range of hearing devices?
No comments:
Post a Comment